Study on antiviral treatments for immunocompromised COVID-19 patients
Part of Infections, Lungs & breathing clinical trials.
This study looks at how well antiviral treatments work in people with weakened immune systems who get COVID-19. It focuses on patients treated with two specific antivirals and aims to understand their outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) with COVID-19, confirmed by a positive PCR test from a nose swab or lung fluid.
- You had symptoms from COVID-19 and were treated with either nirmatrelvir/ritonavir or remdesivir (alone or together).
- You were hospitalized in a regular hospital room or day hospital for your COVID-19 infection.
- You are at very high risk of severe COVID-19 because of conditions like certain blood cancers, organ or stem cell transplant, or a weakened immune system.
- You were taking a long-term (at least 3 months) immunosuppressive medication, such as anti-cancer drugs or high-dose steroids, during your infection.
- You did not receive convalescent plasma as your first treatment for COVID-19.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
This trial tests a longer course of remdesivir plus Paxlovid (nirmatrelvir/ritonavir) for immunocompromised people with persistent COVID-19. It aims to see if combining these two antiviral medicines can help clear the virus more effectively.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.
This study looks at how the body's immune system reacted to COVID-19 in people who had either severe or mild cases. The goal is to learn more about a specific part of the immune response (called IFN-I) to better understand the disease.
Hear when a new Immunocompromised Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.